Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACA | Q13085 | 12/20 | 0.64 |
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.33 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834595 | 0.83 | ACACA (0.77) | ACACAACACB | |
| SCHEMBL19834484 | 0.83 | ACACA (0.71) | ACACAACACBFFAR1PPARD | |
| SCHEMBL19834603 | 0.80 | ACACA (0.69) | ACACAACACB | |
| SCHEMBL19834402 | 0.79 | ACACA (0.53) | ACACAACACBFFAR1PPARD | |
| SCHEMBL19834538 | 0.78 | ACACA (1.00) | ACACAACACB | |
| SCHEMBL19834495 | 0.78 | ACACA (0.67) | ACACAACACBFFAR1PPARD | |
| SCHEMBL19834348 | 0.77 | ACACA (0.71) | ACACAACACB | |
| SCHEMBL19834574 | 0.76 | ACACA (0.56) | ACACAACACBFFAR1PPARDPARP15 | |
| SCHEMBL19834487 | 0.76 | ACACA (0.69) | ACACAACACB | |
| SCHEMBL19834465 | 0.75 | ACACA (0.71) | ACACAACACBFFAR1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-09 | — | — | US | disclosed |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279183-A1 | MONOCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10252997-B2 | Monocyclic compound | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885FFAR1 110/4885 |
| US-20180079723-A1 | MONOCYCLIC COMPOUND | FABP1, CPT1A, GOT2 | ACACA 58/4885ACACB 28/4885FFAR1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.